Considering the path.Understanding the risk.
Company-published, illustrative five-year scenarios for REGEN001. Projections are not guarantees of future performance.
Explore the scenarios
COMPANY-PUBLISHED ILLUSTRATIONS
Five-year investment scenarios.
These figures reproduce scenarios published on Apterna’s existing website. They are assumptions, not independently verified forecasts or promises of return. An investment may be lost in full.
March 2026 · Current published revision
| Scenario | Assumed status | Valuation | Stake value | Multiple | Probability range |
|---|---|---|---|---|---|
| Conservative | Phase 2a enrolling | £80–150M | £14–33M | 2.8–6.6× | 25–30% |
| Base case | Phase 2a data; deal | £175–300M | £30–66M | 6–13.2× | 20–25% |
| Optimistic | Deal closed | £300–500M+ | £45–100M | 9–20× | 10–15% |
Published expected-value range: £10–18M. The initial source also assumes approximately 29% entry ownership. These values are reproduced, not recalculated.
How to read these scenarios
Future company valuation, ownership dilution, development milestones, transaction outcomes, and probabilities are uncertain. The source describes a revision following published in vivo research; it does not establish that REGEN001 has demonstrated clinical benefit in humans.
Human translation and delivery in cirrhotic liver remain development considerations. Use formal current materials and independent advice for any investment assessment.
CONTINUE EXPLORING
